每年專案
個人檔案
學歷
- 2010 高雄醫學大學生物醫學研究所博士
- 2005 高雄醫學大學生物醫學研究所碩士
- 2004 高雄醫學大學生物醫學暨環境生物學系學士
經歷
- 2022- 臺北醫學大學生藥學研究所教授
- 2017-2022 臺北醫學大學生藥學研究所副教授
- 2016-2017 臺北醫學大學生技醫療產業研發博士學位學程助理教授
- 2015-2017 臺北醫學大學轉譯醫學博士學位學程助理教授
- 2013- 臺北醫學大學中草藥臨床藥物研發博士學位學程
- 2013- 臺北醫學大學臨床藥物基因體學暨蛋白質體學碩
- 2012-2017 臺北醫學大學生藥學研究所助理教授
- 2010-2011 高雄海洋科技大學水產養殖系兼任助理教授
獎項
- 2021 科技部吳大猷先生紀念獎_藥學領域
-
2020 國家新創獎_新創精進
- 2019 國家新創獎_學研新創
- 2012 戰國策創業競賽 (特優獎)
- 2008 國家新創獎 (第一名)
指紋
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
-
開發人類化拮抗型BACE-2抗體及其衍生PD-L1融合蛋白新藥之新穎胰島保護策略以全面應用於第一型與第二型糖尿病治療(2/3)
Chuang, K.-H. (PI)
8/1/24 → 7/31/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
開發人類化拮抗型BACE-2抗體及其衍生PD-L1融合蛋白新藥之新穎胰島保護策略以全面應用於第一型與第二型糖尿病治療(1/3)
Chuang, K.-H. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
開發可刺激胰島beta細胞增生之拮抗型BACE-2抗體以改善第二型糖尿病(3/3)
Chuang, K.-H. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
開發可刺激胰島beta細胞增生之拮抗型BACE-2抗體以改善第二型糖尿病(2/3)
Chuang, K.-H. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
乳癌細胞α9尼古丁受體作為新穎靶向RNA奈米藥物與T細胞療法之臨床轉譯研究-開發抗α9尼古丁受體/抗CD3雙功能抗體以一步驟建構可高效標靶毒殺乳癌腫瘤之武裝型T細胞免疫療法(3/3)
Chuang, K.-H. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safety
Liao, T. Y., Liu, Y. L., Chen, C. Y., Wu, B. T., Liu, E. S., Hong, S. T., Huang, B. C., Cheng, Y. A., Chen, M., Chuang, K. H., Lin, W. W., Chuang, C. H., Chen, F. M., Ho, K. W. & Cheng, T. L., 5月 2025, 於: International Journal of Biological Macromolecules. 305, 141003.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Melatonin reverses bisphenol A-induced toxicity in granulosa cells: Restoration of FSHR and connexin 43 expression
Lin, T. C., Wang, K. H., Chuang, K. H., Kao, A. P. & Kuo, T. C., 2025, (接受/付印) 於: Taiwanese Journal of Obstetrics and Gynecology. 64, 3, p. 469-476 8 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model
Wei, P. S., Chou, P. Y., Hsu, H. Y., Chen, M., Chen, Y. J., Tsai, T. H., Wen, B. Y., Sheu, M. T., Chuang, K. H. & Lin, H. L., 2025, 於: International Journal of Nanomedicine. 20, p. 3083-3111 29 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Celecoxib attenuates interleukin 33-induced expression of vascular cell adhesion molecule-1 in human ovarian endometriotic stromal cells
Lin, T. C., Wang, K. H., Chuang, K. H., Kao, A. P. & Kuo, T. C., 3月 2024, 於: Taiwanese Journal of Obstetrics and Gynecology. 63, 2, p. 178-185 8 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯(Scopus) -
The angiogenic role of the alpha 9-nicotinic acetylcholine receptor in triple-negative breast cancers
Ochirbat, S., Kan, T. C., Hsu, C. C., Huang, T. H., Chuang, K. H., Chen, M., Cheng, C. C., Chang, C. C., Rahayu, S. & Chang, J., 2024, (接受/付印) 於: Angiogenesis. 27, 4, p. 827-843 17 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯(Scopus)
資料集
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Su, C.-Y. (Contributor), Chen, M. (Contributor), Chen, L.-C. (Contributor), Ho, Y.-S. (Contributor), Ho, H.-O. (Contributor), Lin, S.-Y. (Contributor), Chuang, K.-H. (Contributor) & Sheu, M.-T. (Contributor), Unknown Publisher, 5月 2 2018
DOI: 10.6084/m9.figshare.6213620.v1, https://tandf.figshare.com/articles/Bispecific_antibodies_anti-mPEG_anti-HER2_for_active_tumor_targeting_of_docetaxel_DTX_-loaded_mPEGylated_nanocarriers_to_enhance_the_chemotherapeutic_efficacy_of_HER2-overexpressing_tumors/6213620/1
資料集: Dataset
-
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Hsieh, Y.-C. (Creator), Liao, J.-M. (Creator), Chuang, K.-H. (Creator), Ho, K.-W. (Creator), Hong, S.-T. (Creator), Liu, H.-J. (Creator), Huang, B.-C. (Creator), Chen, I.-J. (Creator), Liu, Y.-L. (Creator), Wang, J.-Y. (Creator), Tsai, H.-L. (Creator), Su, Y.-C. (Creator), Wang, Y.-T. (Creator) & Cheng, T.-L. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.c.5819661.v1, https://springernature.figshare.com/collections/A_universal_in_silico_V_D_J_recombination_strategy_for_developing_humanized_monoclonal_antibodies/5819661/1
資料集: Dataset
-
Additional file 1 of A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Wang, Y.-T. (Creator), Huang, B.-C. (Creator), Hsieh, Y.-C. (Creator), Ho, K.-W. (Creator), Cheng, T.-L. (Creator), Wang, J.-Y. (Creator), Liu, H.-J. (Creator), Tsai, H.-L. (Creator), Liao, J.-M. (Creator), Liu, Y.-L. (Creator), Hong, S.-T. (Creator), Chen, I.-J. (Creator), Su, Y.-C. (Creator) & Chuang, K.-H. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.19101789.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_A_universal_in_silico_V_D_J_recombination_strategy_for_developing_humanized_monoclonal_antibodies/19101789/1
資料集: Dataset
-
Additional file 1 of Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
Liu, E.-S. (Contributor), Wang, C.-K. (Contributor), Chuang, K.-H. (Contributor), Chen, F.-M. (Creator), Wu, T.-H. (Contributor), Chen, C.-Y. (Creator), Chen, I.-J. (Creator), Lin, R.-A. (Creator), Wang, Y.-M. (Contributor), Lu, Y.-C. (Contributor), Liao, T.-Y. (Contributor), Chen, H.-J. (Creator), Cheng, T.-L. (Creator) & Cheng, Y.-A. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12885938.v1, https://doi.org/10.6084%2Fm9.figshare.12885938.v1
資料集: Dataset
-
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Chen, L.-C. (Contributor), Lin, S.-Y. (Contributor), Sheu, M.-T. (Contributor), Ho, Y.-S. (Contributor), Su, C.-Y. (Contributor), Chen, M. (Contributor), Ho, H.-O. (Contributor) & Chuang, K.-H. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.6213620, https://doi.org/10.6084%2Fm9.figshare.6213620
資料集: Dataset